Rubius Therapeutics Stock Price, News & Analysis (NASDAQ:RUBY) $0.02 0.00 (0.00%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$0.0181▼$0.019050-Day Range$0.02▼$0.0252-Week Range$0.00▼$0.42Volume20,119 shsAverage Volume1.24 million shsMarket Capitalization$1.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaSustainabilityStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaSustainability About Rubius Therapeutics Stock (NASDAQ:RUBY)Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Read More RUBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RUBY Stock News HeadlinesNovember 5, 2023 | morningstar.comRubius Therapeutics Inc RUBYAugust 2, 2023 | uk.finance.yahoo.comRUBY - Rubius Therapeutics, Inc.November 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJuly 25, 2023 | morningstar.comNorth American Morning Briefing: Alphabet, -2-March 2, 2023 | finance.yahoo.comRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On AlternativesFebruary 14, 2023 | marketwatch.comThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?February 14, 2023 | msn.comWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?January 25, 2023 | yahoo.comThe Wrap: Ruby's moving to Congress Street, launching new French conceptNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJanuary 12, 2023 | mirror.co.ukRuby Wax sparks concern from fans after posting video from hospital bedJanuary 12, 2023 | dailymail.co.ukRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookNovember 18, 2022 | finance.yahoo.comFormer Rubius CEO jumps to another Flagship spinoutNovember 4, 2022 | finance.yahoo.comRubius Therapeutics lays off most of its staff, explores saleNovember 3, 2022 | finance.yahoo.comRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic AlternativesNovember 2, 2022 | seekingalpha.comRubius stock falls over 5% after hours on strategic review, more job cutsNovember 2, 2022 | finance.yahoo.comRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesOctober 28, 2022 | finance.yahoo.comRubius Therapeutics, Inc. (RUBY)October 10, 2022 | reuters.comRubius Therapeutics IncSeptember 19, 2022 | bizjournals.comFlagship-backed Vesalius lays off 43%September 19, 2022 | finance.yahoo.comRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 14, 2022 | bizjournals.comRubius Therapeutics lays off 75% of staff, looks to sell Smithfield facilitySeptember 13, 2022 | finance.yahoo.comRubius Therapeutics scraps platform, lays off 160September 13, 2022 | finance.yahoo.comRubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer AssetsSeptember 13, 2022 | seekingalpha.comRubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforceSeptember 13, 2022 | nasdaq.comRubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick FactsSeptember 13, 2022 | finance.yahoo.comRubius Therapeutics Announces Strategic UpdateSeptember 12, 2022 | financialpost.comRubius Therapeutics to Provide Strategic UpdateSee More Headlines Receive RUBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RUBY CUSIPN/A CIK1709401 Webwww.rubiustx.com Phone(508) 543-1720FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.11Miscellaneous Outstanding Shares90,480,000Free Float85,687,000Market Cap$1.72 million OptionableNot Optionable Beta2.23 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Laurence A. Turka M.D. (Age 65)Chief Scientific Officer and Head of Research & Translational Medicine Comp: $626.55kMr. Craig R. Jalbert CIRA (Age 61)President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director Ms. Marissa HanifyDirector of Corporate CommunicationsKey CompetitorsPeak BioNASDAQ:PKBOScinai ImmunotherapeuticsNASDAQ:SCNIBrickell BiotechNASDAQ:BBIZIVO BioscienceNASDAQ:ZIVOIgnyte AcquisitionNASDAQ:IGNYView All CompetitorsInsidersDannielle AppelhansSold 10,385 sharesTotal: $1,350.05 ($0.13/share)Dannielle AppelhansSold 3,878 sharesTotal: $969.50 ($0.25/share)Pablo J CagnoniSold 7,240 sharesTotal: $1,737.60 ($0.24/share)Laurence A TurkaSold 2,593 sharesTotal: $622.32 ($0.24/share)View All Insider Transactions RUBY Stock Analysis - Frequently Asked Questions How have RUBY shares performed in 2023? Rubius Therapeutics' stock was trading at $0.1750 at the beginning of the year. Since then, RUBY shares have decreased by 89.1% and is now trading at $0.0190. View the best growth stocks for 2023 here. How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) earnings per share. What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO? 12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM). When did Rubius Therapeutics IPO? (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are Rubius Therapeutics' major shareholders? Rubius Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship. View institutional ownership trends. How do I buy shares of Rubius Therapeutics? Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RUBY) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.